Implications of the CANVAS Study in Reducing Cardiovascular Outcomes

Ameena Madan Paramasivan, Archana Purushothaman, Cyrus V Desouza

Research output: Contribution to journalReview article

Abstract

Purpose of Review: In recent years, Cardiovascular Outcome Event Trials (CVOTs) in type 2 diabetes mellitus (T2DM) have demonstrated that sodium glucose transporter 2 inhibitors (SGLT2i) could reduce major adverse cardiovascular events (MACE) and cardiovascular mortality independent of a glucose lowering mechanism. SGLT2i trials reported significant results that have generated biologically plausible theories with regard to the macrovascular benefit. In this review, we have summarized and discussed the results of the CANVAS program. Recent Findings: The CANVAS program is unique as it is an analysis of two aggregated cohorts. The two cohorts were similar at baseline but had different durations of exposure to canagliflozin. It showed a 14% reduction in the primary MACE composite. However, the individual components of the MACE composite were not significantly different from placebo. Initial analysis also indicated a reno-protective effect. Summary: The results of the CANVAS program are similar overall yet different when compared to the EMPA-REG OUTCOMES trial, especially with regard to cardiovascular mortality and adverse event profile. This could possibly be due to the differences in the cardiovascular risk profile of the enrolled population in the two trials. Other possibilities include drug-specific effects and different mechanisms of lowering overall MACE. In addition, a brief comparison of CANVAS to the CVD-REAL indicates that the CANVAS trial results may apply to a larger, more generalized population than those in the CANVAS program.

Original languageEnglish (US)
Article number142
JournalCurrent diabetes reports
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Sodium-Glucose Transporter 2
Mortality
Type 2 Diabetes Mellitus
Population
Placebos
Glucose
Pharmaceutical Preparations

Keywords

  • CANAGLIIFLOZIN
  • CANVAS
  • EMPA-REG
  • MACE
  • SGLT2

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Implications of the CANVAS Study in Reducing Cardiovascular Outcomes. / Madan Paramasivan, Ameena; Purushothaman, Archana; Desouza, Cyrus V.

In: Current diabetes reports, Vol. 18, No. 12, 142, 01.12.2018.

Research output: Contribution to journalReview article

Madan Paramasivan, Ameena ; Purushothaman, Archana ; Desouza, Cyrus V. / Implications of the CANVAS Study in Reducing Cardiovascular Outcomes. In: Current diabetes reports. 2018 ; Vol. 18, No. 12.
@article{99e24f156a644659aa7f1a6f629a4544,
title = "Implications of the CANVAS Study in Reducing Cardiovascular Outcomes",
abstract = "Purpose of Review: In recent years, Cardiovascular Outcome Event Trials (CVOTs) in type 2 diabetes mellitus (T2DM) have demonstrated that sodium glucose transporter 2 inhibitors (SGLT2i) could reduce major adverse cardiovascular events (MACE) and cardiovascular mortality independent of a glucose lowering mechanism. SGLT2i trials reported significant results that have generated biologically plausible theories with regard to the macrovascular benefit. In this review, we have summarized and discussed the results of the CANVAS program. Recent Findings: The CANVAS program is unique as it is an analysis of two aggregated cohorts. The two cohorts were similar at baseline but had different durations of exposure to canagliflozin. It showed a 14{\%} reduction in the primary MACE composite. However, the individual components of the MACE composite were not significantly different from placebo. Initial analysis also indicated a reno-protective effect. Summary: The results of the CANVAS program are similar overall yet different when compared to the EMPA-REG OUTCOMES trial, especially with regard to cardiovascular mortality and adverse event profile. This could possibly be due to the differences in the cardiovascular risk profile of the enrolled population in the two trials. Other possibilities include drug-specific effects and different mechanisms of lowering overall MACE. In addition, a brief comparison of CANVAS to the CVD-REAL indicates that the CANVAS trial results may apply to a larger, more generalized population than those in the CANVAS program.",
keywords = "CANAGLIIFLOZIN, CANVAS, EMPA-REG, MACE, SGLT2",
author = "{Madan Paramasivan}, Ameena and Archana Purushothaman and Desouza, {Cyrus V}",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s11892-018-1106-1",
language = "English (US)",
volume = "18",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Implications of the CANVAS Study in Reducing Cardiovascular Outcomes

AU - Madan Paramasivan, Ameena

AU - Purushothaman, Archana

AU - Desouza, Cyrus V

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose of Review: In recent years, Cardiovascular Outcome Event Trials (CVOTs) in type 2 diabetes mellitus (T2DM) have demonstrated that sodium glucose transporter 2 inhibitors (SGLT2i) could reduce major adverse cardiovascular events (MACE) and cardiovascular mortality independent of a glucose lowering mechanism. SGLT2i trials reported significant results that have generated biologically plausible theories with regard to the macrovascular benefit. In this review, we have summarized and discussed the results of the CANVAS program. Recent Findings: The CANVAS program is unique as it is an analysis of two aggregated cohorts. The two cohorts were similar at baseline but had different durations of exposure to canagliflozin. It showed a 14% reduction in the primary MACE composite. However, the individual components of the MACE composite were not significantly different from placebo. Initial analysis also indicated a reno-protective effect. Summary: The results of the CANVAS program are similar overall yet different when compared to the EMPA-REG OUTCOMES trial, especially with regard to cardiovascular mortality and adverse event profile. This could possibly be due to the differences in the cardiovascular risk profile of the enrolled population in the two trials. Other possibilities include drug-specific effects and different mechanisms of lowering overall MACE. In addition, a brief comparison of CANVAS to the CVD-REAL indicates that the CANVAS trial results may apply to a larger, more generalized population than those in the CANVAS program.

AB - Purpose of Review: In recent years, Cardiovascular Outcome Event Trials (CVOTs) in type 2 diabetes mellitus (T2DM) have demonstrated that sodium glucose transporter 2 inhibitors (SGLT2i) could reduce major adverse cardiovascular events (MACE) and cardiovascular mortality independent of a glucose lowering mechanism. SGLT2i trials reported significant results that have generated biologically plausible theories with regard to the macrovascular benefit. In this review, we have summarized and discussed the results of the CANVAS program. Recent Findings: The CANVAS program is unique as it is an analysis of two aggregated cohorts. The two cohorts were similar at baseline but had different durations of exposure to canagliflozin. It showed a 14% reduction in the primary MACE composite. However, the individual components of the MACE composite were not significantly different from placebo. Initial analysis also indicated a reno-protective effect. Summary: The results of the CANVAS program are similar overall yet different when compared to the EMPA-REG OUTCOMES trial, especially with regard to cardiovascular mortality and adverse event profile. This could possibly be due to the differences in the cardiovascular risk profile of the enrolled population in the two trials. Other possibilities include drug-specific effects and different mechanisms of lowering overall MACE. In addition, a brief comparison of CANVAS to the CVD-REAL indicates that the CANVAS trial results may apply to a larger, more generalized population than those in the CANVAS program.

KW - CANAGLIIFLOZIN

KW - CANVAS

KW - EMPA-REG

KW - MACE

KW - SGLT2

UR - http://www.scopus.com/inward/record.url?scp=85056229559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056229559&partnerID=8YFLogxK

U2 - 10.1007/s11892-018-1106-1

DO - 10.1007/s11892-018-1106-1

M3 - Review article

C2 - 30397837

AN - SCOPUS:85056229559

VL - 18

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 12

M1 - 142

ER -